Raymond James & Associates Raises Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV)

Raymond James & Associates grew its position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 6.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 154,829 shares of the biopharmaceutical company’s stock after acquiring an additional 8,729 shares during the period. Raymond James & Associates owned about 0.73% of Achieve Life Sciences worth $638,000 at the end of the most recent quarter.

Separately, Manchester Financial Inc. boosted its holdings in shares of Achieve Life Sciences by 43.9% in the third quarter. Manchester Financial Inc. now owns 18,600 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 5,675 shares in the last quarter. Institutional investors and hedge funds own 33.52% of the company’s stock.

Wall Street Analyst Weigh In

ACHV has been the topic of a number of research analyst reports. Oppenheimer reissued an “outperform” rating and set a $18.00 price objective on shares of Achieve Life Sciences in a report on Monday, April 1st. Jonestrading initiated coverage on shares of Achieve Life Sciences in a report on Wednesday, April 17th. They set a “buy” rating and a $20.00 price objective on the stock. Finally, Lake Street Capital decreased their price objective on shares of Achieve Life Sciences from $19.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, March 5th.

Achieve Life Sciences Stock Performance

Shares of ACHV opened at $4.54 on Thursday. Achieve Life Sciences, Inc. has a 12-month low of $3.03 and a 12-month high of $10.30. The stock has a market cap of $155.50 million, a P/E ratio of -2.97 and a beta of 1.32. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 4.02. The company has a 50-day moving average of $4.42 and a two-hundred day moving average of $4.41.

Achieve Life Sciences (NASDAQ:ACHV) last posted its earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.06. As a group, research analysts predict that Achieve Life Sciences, Inc. will post -0.94 EPS for the current fiscal year.

About Achieve Life Sciences

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.